CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
Assessment of the potential of polyphenols as a CYP17 inhibitor free of adverse corticosteroid elevation. | Semantic Scholar
Mechanisms of resistance to CYP17 inhibitors. Androgen receptor (AR)... | Download Scientific Diagram
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer Stein MN, Patel N, Bershadskiy A, Sokoloff A, Singer EA - Asian J Androl
CYP17A1 inhibitor - Wikipedia
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1 | Drug Metabolism & Disposition
Cytochrome b5 modulation of 17α hydroxylase and 17–20 lyase (CYP17) activities in steroidogenesis in: Journal of Endocrinology Volume 187 Issue 2 (2005)
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer
Mechanisms of resistance to CYP17 inhibitors. Androgen receptor (AR)... | Download Scientific Diagram
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials Cao Q, Bai P, Shi D, Liao J, Shi H, Xing Y, Chen K, Zhang X -
P450 Signaling | CYP450
PDF) CYP17 inhibitors - Abiraterone, C17,20-lyase inhibitors and multi-targeting agents
Cancers | Free Full-Text | Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced? | HTML
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials Cao Q, Bai P, Shi D, Liao J, Shi H, Xing Y, Chen K, Zhang X -
References in Functional characterization of mutant CYP17 genes isolated from a 17α-hydroxylase/17,20-lyase-deficient patient - Metabolism - Clinical and Experimental
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven | Cancer Research
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases - ScienceDirect
Abiraterone (Zytiga): Mechanism of Zytiga
Steroid/androgen synthesis pathway and the sites of inhibition of... | Download Scientific Diagram
The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature - European Urology
